Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 1/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 6/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.32 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.32 |
| ▸ | GRN | P28799 | 1/20 | 0.31 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23997682 | 0.83 | KLKB1 (0.47) | KLKB1DGAT1NPC1MAPT | |
| SCHEMBL17222119 | 0.83 | KLKB1 (0.47) | KLKB1DGAT1NPC1MAPTMCL1 | |
| SCHEMBL5654607 | 0.80 | KLKB1 (0.45) | KLKB1DGAT1NPC1EGLN1 | |
| SCHEMBL27858492 | 0.78 | DGAT1 (0.36) | KLKB1DGAT1PTPN1NPC1 | |
| SCHEMBL29112575 | 0.77 | DGAT1 (0.41) | KLKB1DGAT1NPC1 | |
| SCHEMBL31021702 | 0.76 | DGAT1 (0.34) | KLKB1DGAT1PTPN1NPC1 | |
| SCHEMBL28929773 | 0.75 | DGAT1 (0.35) | KLKB1DGAT1 | |
| SCHEMBL12382013 | 0.75 | DGAT1 (0.45) | KLKB1DGAT1PTPN1NPC1F11 | |
| SCHEMBL17222067 | 0.74 | KLKB1 (0.45) | KLKB1DGAT1NPC1MAPT | |
| SCHEMBL12984274 | 0.74 | KLKB1 (0.41) | KLKB1DGAT1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4405334-B1 | SORTILIN INHIBITORS | SORTINA PHARMA AB (SE) | 2025-02-12 | — | — | EP | disclosed |
| US-20250002460-A1 | SORTILIN INHIBITORS | SORTINA PHARMA AB (SE) | 2025-01-02 | — | — | US | disclosed |
| EP-4405334-A1 | SORTILIN INHIBITORS | Sortina Pharma AB (SE) | 2024-07-31 | — | — | EP | disclosed |
| WO-2023101595-A1 | SORTILIN INHIBITORS | SORTINA PHARMA AB (SE) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002460-A1 | SORTILIN INHIBITORS | SORT1, GRN, SCARB1 | KLKB1 1132/4885DGAT1 3525/4885PTPN1 2575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.